Methods for reducing and/or preventing de-chelation of a chelated radioisotope
AssigneeCuradel Surgical Innovations, Inc.
InventorJohn V. Frangioni
Life of this patent
Estimating the term…
Abstract
In accordance with at least one aspect of this disclosure, a method includes reducing a probability of de-chelation of a metal or metal isotope from a chelating radiotherapeutic including a chelating radioisotope and a metal chelator during one or more of: electronic conversion of the chelating radioisotope and/or radioactive decay of the chelating radioisotope by including one or more zwitterionic group on the metal chelator.
Claims28
A method, comprising:
- reducing a probability of de-chelation of a metal or metal isotope from a chelating radiotherapeutic comprising a chelating radioisotope and a metal chelator during one or more of:
- electronic conversion of the chelating radioisotope and/or radioactive decay of the chelating radioisotope by including one or more zwitterionic groups on the metal chelator.
A method of improving efficacy and/or reducing an off-target dose of a chelating radiotherapeutic, comprising:
- preparing a chelating radiotherapeutic having at least a chelating radioisotope and a metal chelator;
- selecting the metal chelator for inclusion on the chelating radiotherapeutic based at least in part on a probability of de-chelation of a metal or metal isotope from the metal chelator during transition of the radioisotope;
- and
- including one or more zwitterionic groups on the metal chelator.
13-17. (canceled)
An improved radiopharmaceutical for the treatment and/or diagnosis of cancer in a patient, comprising;
- a chelating radiopharmaceutical having a chelating radioisotope;
- a metal chelator included on the chelating radioisotope and one or more zwitterionic groups included in the metal chelator, the metal chelator selected on a basis of a probability of de-chelation of a metal or metal isotope from the chelating radiopharmaceutical during one or more of:
- electronic conversion of the chelating radioisotope and/or due to excess energy generated from alpha particle emission from radioactive decay of the chelating radioisotope, where inclusion of the one or more zwitterionic groups reduces the probability of de-chelation, thereby decreasing an off-target radiation dose and increasing targeted cell uptake of the dose and maximizing an efficacy of the radiopharmaceutical.
30-32. (canceled)
34-36. (canceled)
Dependencies are inferred from the claim text.